U.S., Nov. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07224009) titled 'Low Dose Naltrexone (LDN) for Management of Fatigue in Prostate Cancer Patients on Androgen Deprivation Therapy (ADT)' on Oct. 29.
Brief Summary: We want to see if a small daily dose of naltrexone (LDN, 3 mg pill) can help reduce tiredness (fatigue) in men with prostate cancer. All men in this study are being treated with hormone therapy (also called androgen deprivation therapy, or ADT). Some may also be taking newer hormone medicines such as apalutamide, daralutamide, enzalutamide, or abiraterone.
Study Start Date: Jan., 2026
Study Type: INTERVENTIONAL
Condition:
Metastatic Prostate Cancer
Intervention:
DRUG: Naltrexone
Nalt...